1.47
0.00%
Close of 30 Oct 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Pangaea Oncology
Its shares trade on BME under the ticker PANG.MC. It has been listed since 29 December 2016. In the fiscal year to 31 December 2025, it reported revenue of €14.5m and a net loss of €3.6m. At that date it held total assets of €32.1m and shareholders' equity of €21.3m.
Pangaea Oncology SA provides molecular diagnostics and research development services in the field of personalized cancer treatment. The company is headquartered in Barcelona, Barcelona. The company went IPO on 2016-12-29. The firm focuses on the development of oncology treatments. The Company’s activities are divided into two business lines: Clinical care in the Dr. Rosell Oncology Institute (IOR) and Molecular diagnosis (Dx). The IOR division offers personalized medical services related to oncology area, such as diagnosis, laboratory testing and treatment, in a chain of hospitals in Catalonia, Spain. The Dx division is responsible for the development of diagnostic and in-vitro services, biomarkers, as well as targeted drugs for patients and pharmaceutical companies. Its diagnostic models include Liquid Biopsy and Multiplexing.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 29 Dec 2016
- Employees
- 48
- Website
- panoncology.com ↗
Leadership
Pay as last reported
- Mr. Rafael Rosell CostaExecutive Chairman of the Board, Representative of Topgenetics, SLU, Co-Founder, Chief Scientific Officer, since 2016
- Mr. Javier Rivela RodriguezChief Executive Officer, Co-Founder, Executive Director, since 2016
- Mr. Santiago Ramon y Cajal AguerasVice Chairman of the Board, Proprietary Director, Representative of Biolifepat, SL, since 2016
- Mr. Jose Antonio Maestre AlcacerProprietary Director, Representative of Maectorax, SL, Co-Founder, Executive Officer (Thoracic Surgery), since 2016
- Mr. Alejandro Garcia MoncayoExecutive Director, Corporate and Chief Financial Officer
- Ms. Paula BarcosExecutive Officer (Pneumology)
- Ms. Leire IzaguirreExecutive Officer (Clinical Operations)
- Ms. Elvira BuxoChief of Staff of IOB, Teknon
- Mr. Lluis CireraChief of Staff of Hospital Universitario Sagrat Cor
- Mr. Xavier GonzalezChief of Staff of Hospital General de Catalunya
- Mr. Jordi MartiExecutive Director - IOB, Institutional Relations
- Mr. Alejandro MartinezExecutive Director - Clinical Trials, Chief of Staff of Dexeus Hospital
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Pangaea Oncology SA has several strengths that contribute to its success in the market. These strengths include a strong research and development team dedicated to advancing oncology treatments, a wide network of partnerships with leading medical institutions, and a comprehensive portfolio of innovative cancer diagnostic and therapeutic solutions. Additionally, the company benefits from a well-established reputation for delivering high-quality and accurate cancer diagnoses, which has gained the trust of patients and healthcare professionals alike.
Weaknesses
- Despite its strengths, Pangaea Oncology SA also faces certain weaknesses that need to be addressed. One of the main weaknesses is its limited geographical presence, primarily focusing on the European market. Expanding into other regions would provide access to a larger customer base and greater revenue potential. Furthermore, the company heavily relies on external collaborations, which can result in potential delays or dependence on partners. This could hamper the company's ability to control timelines and outcomes.
Opportunities
- Pangaea Oncology SA has several opportunities in the ever-evolving oncology industry. With the increasing prevalence of cancer worldwide, there is a growing demand for advanced diagnostic and treatment solutions. The company can leverage its expertise and portfolio to capture a larger market share. Additionally, expanding into emerging markets, such as Asia and Latin America, presents significant opportunities for growth. Moreover, advancements in technologies like precision medicine and genomics provide opportunities to develop personalized therapies, enhancing patient outcomes.
Threats
- Pangaea Oncology SA faces certain threats that can impact its operations and growth potential. Intense competition from established players in the oncology industry, as well as emerging startups, poses a challenge. The company needs to continuously innovate and differentiate itself to stay ahead. Moreover, changes in healthcare regulations and reimbursement policies can significantly impact market access and profitability. Economic downturns, decreasing healthcare budgets, and reimbursement limitations can also pose threats to the company's revenue stream and financial stability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.